Abeona Therapeutics Inc ABEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
Trading Information
- Previous Close Price
- $2.29
- Day Range
- $2.09–2.44
- 52-Week Range
- $2.09–7.65
- Bid/Ask
- $2.35 / $2.43
- Shares Outstanding
- 61.64M
- Market Cap
- $149.17M
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 226
Valuation
Metric | ABEO |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.10 |
Price/Sales | 3.70 |
Price/Cash Flow | — |
Price/Earnings
ABEO
Financial Strength
Metric | ABEO |
|---|---|
Quick Ratio | 5.46 |
Current Ratio | 5.69 |
Interest Coverage | −22.34 |
Quick Ratio
ABEO
Profitability
Metric | ABEO |
|---|---|
Return on Assets (Normalized) | −28.54% |
Return on Equity (Normalized) | −39.15% |
Return on Invested Capital (Normalized) | −36.18% |
Return on Assets
ABEO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|GgLMm?^ | LOCK|g>?h< | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|qYjYQ< | LOCK|#?#Q | $99B | |||
| Moderna Inc MRNA | LOCK|qJGjV>L | LOCK|vsX | $90B | |||
| argenx SE ADR ARGX | LOCK|nPbV>R | LOCK|vn | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|h<T$#s | LOCK|LjD | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|SRp#N#J | LOCK|r$<>< | $31B | |||
| Incyte Corp INCY | LOCK|rszXb%> | LOCK|Z?? | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|!St%c%% | LOCK|pZ#%Q | $22B | |||
| BioNTech SE ADR BNTX | LOCK|@gBmF!k | LOCK|!$ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|h%%zkw< | LOCK|tW% | $16B |
United States